Gujarat Themis Biosyn completes MicroBiopharm Japan acquisition
In short
Gujarat Themis Biosyn has finished buying 100% of MicroBiopharm Japan Co. through its Japan subsidiary.
The company now fully owns the Japan-based business. The reporting does not give the price, the closing date, or why the deal was done.
What the reporting says
Gujarat Themis Biosyn completed the acquisition of 100% equity shareholding in MicroBiopharm Japan Co. through its wholly owned subsidiary Themis Biosyn Japan, according to the available reporting. The report identifies the target as Japan-based but does not state the deal value, closing date, or strategic rationale. The immediate consequence is a completed overseas acquisition.
Why it matters
Gujarat Themis Biosyn said it completed the acquisition of 100% equity shareholding in MicroBiopharm Japan Co. via its wholly owned subsidiary Themis Biosyn Japan. The available reporting does not state the transaction value, closing date, or operational impact. The main effect is that the company has fully brought the Japan-based entity under its ownership.